27,953 Shares in AMAG Pharmaceuticals, Inc. (AMAG) Purchased by AlphaMark Advisors LLC

AlphaMark Advisors LLC purchased a new stake in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 27,953 shares of the specialty pharmaceutical company’s stock, valued at approximately $559,000. AlphaMark Advisors LLC owned approximately 0.08% of AMAG Pharmaceuticals at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. State of Wisconsin Investment Board grew its position in shares of AMAG Pharmaceuticals by 34.6% in the second quarter. State of Wisconsin Investment Board now owns 35,000 shares of the specialty pharmaceutical company’s stock valued at $682,000 after purchasing an additional 9,000 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of AMAG Pharmaceuticals by 6.2% in the second quarter. Renaissance Technologies LLC now owns 1,641,100 shares of the specialty pharmaceutical company’s stock valued at $32,001,000 after purchasing an additional 96,300 shares in the last quarter. Employees Retirement System of Texas grew its position in shares of AMAG Pharmaceuticals by 13.6% in the second quarter. Employees Retirement System of Texas now owns 75,000 shares of the specialty pharmaceutical company’s stock valued at $1,463,000 after purchasing an additional 9,000 shares in the last quarter. First Trust Advisors LP grew its position in shares of AMAG Pharmaceuticals by 106.8% in the second quarter. First Trust Advisors LP now owns 70,869 shares of the specialty pharmaceutical company’s stock valued at $1,382,000 after purchasing an additional 36,607 shares in the last quarter. Finally, Sei Investments Co. grew its position in shares of AMAG Pharmaceuticals by 1,695.3% in the second quarter. Sei Investments Co. now owns 506,429 shares of the specialty pharmaceutical company’s stock valued at $9,876,000 after purchasing an additional 478,220 shares in the last quarter.

Several research analysts recently weighed in on AMAG shares. Zacks Investment Research lowered AMAG Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Friday, October 5th. Cantor Fitzgerald set a $18.00 price objective on AMAG Pharmaceuticals and gave the stock a “hold” rating in a research report on Wednesday, September 26th. BidaskClub lowered AMAG Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 25th. Deutsche Bank set a $23.00 price objective on AMAG Pharmaceuticals and gave the stock a “hold” rating in a research report on Thursday, September 20th. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $22.00 price objective on shares of AMAG Pharmaceuticals in a research report on Friday, August 3rd. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $21.97.

Shares of AMAG Pharmaceuticals stock opened at $17.57 on Wednesday. The company has a market capitalization of $630.51 million, a P/E ratio of -3.08 and a beta of 0.23. AMAG Pharmaceuticals, Inc. has a fifty-two week low of $11.95 and a fifty-two week high of $26.10. The company has a quick ratio of 2.72, a current ratio of 2.86 and a debt-to-equity ratio of 0.34.

AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings data on Thursday, November 1st. The specialty pharmaceutical company reported ($1.88) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($1.11). The business had revenue of $122.20 million during the quarter, compared to analysts’ expectations of $118.23 million. AMAG Pharmaceuticals had a negative return on equity of 13.65% and a negative net margin of 6.98%. The company’s revenue was down 1.7% on a year-over-year basis. During the same quarter in the previous year, the company posted ($4.31) earnings per share. Equities research analysts predict that AMAG Pharmaceuticals, Inc. will post -2.58 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Enterprise Leader and is owned by of Enterprise Leader. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://theenterpriseleader.com/2018/11/07/27953-shares-in-amag-pharmaceuticals-inc-amag-purchased-by-alphamark-advisors-llc.html.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.

Featured Article: How are Outstanding Shares Different from Authorized Shares?

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply